Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS-5346, the centerpiece of a USD 1.97 billion...
Merck
Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval
Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. FDA...
Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
Merck KGaA (ETR: MRK) announced that China’s National Medical Products Administration (NMPA) granted priority review approval...
Valo Health Partners with Merck on $3B Parkinson’s Disease Discovery Deal
Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic...
Abbisko Therapeutics Reports Durable Response in Phase 3 MANEUVER Study for Pimicotinib (ABSK021) in TGCT
Abbisko Therapeutics Co., Ltd. (HKG: 2256) released long‑term efficacy, safety and patient‑reported outcome data from its...
Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC
Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...
Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition
Merck KGaA (ETR: MRK) announced that Kai Beckmann will assume the roles of Chair of...
Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products...
Biocytogen, Merck Partner on Antibody‑Conjugated Lipid Nanoparticles
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has signed an evaluation...
MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) disclosed encouraging topline results from the...
Skyhawk Therapeutics Collaborates with Merck on RNA-Targeting Small Molecules for Neurological Diseases
Skyhawk Therapeutics, Inc. announced on August 18, 2025, a strategic research collaboration with Merck KGaA...
Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition
Germany-based multinational Merck KGaA (ETR: MRK) reported Q2 2025 financial results, which were significantly affected...
Pascal Qian Appointed General Manager of BMS China Unit
Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...
Merck’s Pimicotinib NDA Accepted for Review by China’s CDE
German pharmaceutical major Merck KGaA (ETR: MRK) announced that the New Drug Application (NDA) for...
Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China
China’s Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced a collaboration agreement with Merck KGaA...
Merck KGaA Partners with IMEC to Develop Advanced Microphysiological Systems Platform
German major Merck KGaA (ETR: MRK) this week announced a partnership with Belgium-based Interuniversity Microelectronics Centre...
Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...
Merck KGaA and JD Health Launch Online Thyroid Care Center in China
The Thyroid Care Center on the JD Health platform, a joint initiative between German pharmaceutical...
Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China
Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...
Merck KGaA Nears Completion of $3.5 Billion Acquisition of SpringWorks Therapeutics
German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of...